• Explore /
  • Poster
  • / The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886)  plus  irinotecan (IRI)  as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).

The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886)  plus  irinotecan (IRI)  as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).

Abstract Poster

Authors

null

Howard S. Hochster

Yale School of Medicine, New Haven, CT

Howard S. Hochster , Wells A. Messersmith , Bert H. O'Neil , Susan G. Groshen , Heinz-Josef Lenz , Deirdre Jill Cohen , Crystal Shereen Denlinger , Philip Jordan Gold , S. Gail Eckhardt , Gershon Y. Locker , Patricia Ames , Marti McKinley , Lawrence P. Leichman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Citation

J Clin Oncol 31, 2013 (suppl; abstr 3587)

DOI

10.1200/jco.2013.31.15_suppl.3587

Abstract #

3587

Poster Bd #

7E

Abstract Disclosures

Similar Posters

First Author: Howard Hochster

First Author: Vanessa Wong

First Author: Patrick M Boland

First Author: Jin Li